%0 Journal Article
%A Almeida, Ludmila Santiago
%A Etchebehere, Elba Cristina Sá de Camargo
%A García Megías, Irene
%A Calapaquí Terán, Adriana K
%A Hadaschik, Boris
%A Colletti, Patrick M
%A Herrmann, Ken
%A Giammarile, Francesco
%A Delgado Bolton, Roberto C
%T PSMA Radioligand Therapy in Prostate Cancer: Where Are We and Where Are We Heading?
%J Clinical nuclear medicine
%V 49
%N 1
%@ 0363-9762
%C [Erscheinungsort nicht ermittelbar]
%I Ovid
%M DKFZ-2023-02180
%P 45-55
%D 2024
%Z 2024 Jan 1;49(1):45-55
%X Diagnosis and treatment of prostate cancer are complex and very challenging, being a major health care burden. The efficacy of radioligand therapy with prostate-specific membrane antigen agents has been proven beneficial in certain clinical indications. In this review, we describe management of prostate cancer patients according to current guidelines, especially focusing on the available clinical evidence for prostate-specific membrane antigen radioligand therapy.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37882758
%R 10.1097/RLU.0000000000004919
%U https://inrepo02.dkfz.de/record/285007